• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Researchers develop 3D-printed, bioabsorbable scaffold for ACL reconstruction

February 27, 2017 By Sarah Faulkner

Researchers develop 3D-printed, bioabsorbable scaffold for ACL reconstructionResearchers at the Mayo Clinic‘s tissue engineering and biomaterials laboratory have developed a 3D-printed, porous scaffold for the delayed delivery of recombinant-human bone morphogenetic protein 2, rhBMP-2, to facilitate bone regeneration in patients undergoing ACL reconstruction.

The team’s work developing the scaffold and comparing different delivery methods for rhBMP-2 was published this week in Tissue Engineering. 

The 3D-printed scaffold is 3mm in diameter and 10mm in length, with 300μm pores. The researchers created 4 scaffold designs with increasing porosity at 0%, 20%, 35% and 44%.

Testing the strength of the scaffold in a rabbit ACL reconstruction model, the team found that “the 20% scaffold maintained the greatest pullout strength compared to the solid screw, while the pullout strength of the 35% and 44% scaffolds decreased by half.”

The team also tested 4 methods for embedding and delivering the rhBMP-2, including microspheres, collagen and a saline solution.

“The microsphere delivery groups had a smaller burst release and released a smaller percentage of rhBMP-2 over the 32 days than the collagen and saline only groups,” the authors wrote. “Combining a synthetic bone mineral coating with microspheres had an additive effect, decreasing the initial burst release and cumulative release of rhBMP-2.”

“This work is a good example of the fusion of technologies – controlled release drug delivery and 3D printing,” Tissue Engineering co-editor-in-chief Dr. Peter Johnson added in prepared remarks.

The protein is the same used in Medtronic‘s (NYSE:MDT) InFuse bone graft and the team’s work could provide insight into how to delay the protein’s release – a problem that is at heart of InFuse’s controversial history.

In 2008, InFuse sparked a furor over concerns that the product’s sales were driven primarily by active promotion of off-label uses and in 2011, the company dealt with a spate of lawsuits and a Spine Journal issue dedicated entirely to concerns about the bone graft’s safety.

The U.S. Justice Dept. and the U.S. Senate investigated the bone morphogenetic compound and its Fridley, Minn.-based maker’s marketing practices, but eventually an independent study found that InFuse is equivalent to iliac crest bone grafts.

The study also determined that Medtronic-sponsored trials of the product were biased and in 2015, the company inked a $22 million deal to settle about 950 InFuse lawsuits.

A report from the Minneapolis Star Tribune in April 2016 revealed that a 2-year review of some 3,647 InFuse patients in 2008 turned up nearly 1,000 adverse events that weren’t reported to the FDA until 2013.

Medtronic later explained the 5-year delay, after prodding from Sens. Al Franken (D-Minn.) and Amy Klobuchar (D-Minn.), saying that the delay was inadvertent.

Filed Under: Featured, Orthopedics, Regenerative Medicine, Research & Development Tagged With: Mayo Clinic, Medtronic

IN CASE YOU MISSED IT

  • BD files patent infringement lawsuit against Baxter over infusion pump tech
  • Tandem Diabetes Care subsidiary earns new FDA clearance for insulin infusion set
  • Glucotrack can proceed with long-term glucose monitor study in Australia
  • Dexcom promotes Jake Leach to president role
  • Roche invests $550M to make Indianapolis a CGM manufacturing hub

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS